{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T07:45:45Z","timestamp":1790754345287,"version":"4.1.0"},"reference-count":60,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T00:00:00Z","timestamp":1769040000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>In the KEYNOTE-966 study, the clinical benefits of pembrolizumab plus chemotherapy were demonstrated for patients with advanced biliary tract cancer (BTC). At this point, it is unknown whether this expensive therapy is cost-effective. The purpose of this study was to evaluate the cost-effectiveness of pembrolizumab plus chemotherapy in treating BTC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We constructed a partitioned survival model form the perspectives of US and Chinese payers. KEYNOTE-966 was used to obtain the baseline characteristics of the patients as well as their clinical data. Local databases and published literature were used to collect costs and utilities. Costs, life years, quality-adjusted life years (QALYs), incremental cost-effectiveness ratios (ICERs), incremental net health benefits (INHB), and incremental net monetary benefits (INMB) were measured and compared. We conducted sensitivity analyses in order to assess the robustness of the model. Subgroup analyses were also performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Pembrolizumab plus chemotherapy is not cost-effective in China at the willingness to pay (WTP) thresholds of $38,258 and $84,866. However, it yielded an additional 0.137 QALYs and an additional $63,864 (ICER $466,340) over chemotherapy alone. In the US, this treatment was not cost-effective, resulting in an improvement in effectiveness of 0.144 QALYs and an increase in overall cost of $141,000 (ICER of $976,925). There were INHBs of \u22120.616 QALYs and INMBs of -$52,237 for pembrolizumab plus chemotherapy in China if the WTP threshold for QALYs was set at $84,866, and INHBs of \u22120.796 QALYs and INMBs of -$119,400 when the WTP threshold was set at $150,000 for the US. Through sensitivity analyses, it was demonstrated that the results were stable. The results of the subgroup analysis indicate that better survival properties subgroups were more likely to be cost-effective, although pembrolizumab plus chemotherapy may not be cost-effective for all subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In the US and China, pembrolizumab plus chemotherapy may not be a cost-effective treatment option. This study provides evidence-based pricing strategies that may benefit decision makers and clinicians as they make clinical decisions. For a better understanding of the impact on budgets and the affordability of care for patients, more evidence is required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0341154","type":"journal-article","created":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:29:06Z","timestamp":1769106546000},"page":"e0341154","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["A cost-effectiveness analysis comparing pembrolizumab combined with chemotherapy versus chemotherapy alone for advanced biliary tract cancer: US and China perspectives"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-5729-7670","authenticated-orcid":true,"given":"Chunhua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanni","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolan","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqing","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumei","family":"Nong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,1,22]]},"reference":[{"issue":"10272","key":"pone.0341154.ref001","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/S0140-6736(21)00153-7","article-title":"Biliary tract cancer","volume":"397","author":"JW Valle","year":"2021","journal-title":"Lancet"},{"issue":"6","key":"pone.0341154.ref002","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1053\/j.gastro.2013.10.013","article-title":"Pathogenesis, diagnosis, and management of cholangiocarcinoma","volume":"145","author":"SI Ilyas","year":"2013","journal-title":"Gastroenterology"},{"key":"pone.0341154.ref003","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.2147\/CMAR.S157092","article-title":"Biliary tract cancers: current knowledge, clinical candidates and future challenges","volume":"11","author":"N-U-A Tariq","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"11","key":"pone.0341154.ref004","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S2468-1253(21)00171-0","article-title":"Current and emerging therapies for advanced biliary tract cancers","volume":"6","author":"AE Kam","year":"2021","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"pone.0341154.ref005","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.jhep.2019.09.007","article-title":"Risk factors for intrahepatic and extrahepatic cholangiocarcinoma: a systematic review and meta-analysis","volume":"72","author":"O Clements","year":"2020","journal-title":"J Hepatol"},{"issue":"10","key":"pone.0341154.ref006","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"A Jusakul","year":"2017","journal-title":"Cancer Discov"},{"issue":"3","key":"pone.0341154.ref007","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"72","author":"S Job","year":"2020","journal-title":"Hepatology"},{"key":"pone.0341154.ref008","article-title":"Projections of lung cancer incidence by 2035 in 40 countries worldwide: population-based study","volume":"9","author":"G Luo","year":"2023","journal-title":"JMIR Public Health Surveill"},{"issue":"3","key":"pone.0341154.ref009","first-page":"209","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"pone.0341154.ref010","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1186\/s12876-022-02637-8","article-title":"The epidemiological trends of biliary tract cancers in the United States of America","volume":"22","author":"Y Jiang","year":"2022","journal-title":"BMC Gastroenterol"},{"issue":"5","key":"pone.0341154.ref011","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise","volume":"21","author":"SK Saha","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"pone.0341154.ref012","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/nrclinonc.2017.157","article-title":"Cholangiocarcinoma - evolving concepts and therapeutic strategies","volume":"15","author":"SI Ilyas","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"pone.0341154.ref013","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1093\/oncolo\/oyac150","article-title":"Temporal changes in cholangiocarcinoma incidence and mortality in the United States from 2001 to 2017","volume":"27","author":"M Javle","year":"2022","journal-title":"Oncologist"},{"issue":"14","key":"pone.0341154.ref014","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"J Valle","year":"2010","journal-title":"N Engl J Med"},{"issue":"3","key":"pone.0341154.ref015","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1200\/JCO.21.00679","article-title":"Modified FOLFIRINOX versus CISGEM chemotherapy for patients with advanced biliary tract cancer (PRODIGE 38 AMEBICA): a randomized phase II study","volume":"40","author":"JM Phelip","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1","key":"pone.0341154.ref016","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1002\/jhbp.1219","article-title":"Randomized phase III study of gemcitabine, cisplatin plus S-1 versus gemcitabine, cisplatin for advanced biliary tract cancer (KHBO1401- MITSUBA)","volume":"30","author":"T Ioka","year":"2023","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"5","key":"pone.0341154.ref017","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial","volume":"22","author":"A Lamarca","year":"2021","journal-title":"Lancet Oncol"},{"issue":"11","key":"pone.0341154.ref018","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1016\/S1470-2045(21)00486-1","article-title":"Liposomal irinotecan plus fluorouracil and leucovorin versus fluorouracil and leucovorin for metastatic biliary tract cancer after progression on gemcitabine plus cisplatin (NIFTY): a multicentre, open-label, randomised, phase 2b study","volume":"22","author":"C Yoo","year":"2021","journal-title":"Lancet Oncol"},{"issue":"3","key":"pone.0341154.ref019","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2206834","article-title":"Futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma","volume":"388","author":"L Goyal","year":"2023","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0341154.ref020","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"M Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"17","key":"pone.0341154.ref021","doi-asserted-by":"crossref","first-page":"1974","DOI":"10.1200\/JCO.2014.59.4358","article-title":"Immune checkpoint blockade in cancer therapy","volume":"33","author":"MA Postow","year":"2015","journal-title":"J Clin Oncol"},{"issue":"6","key":"pone.0341154.ref022","doi-asserted-by":"crossref","first-page":"185","DOI":"10.31083\/j.fbl2706185","article-title":"The state of therapy modalities in clinic for biliary tract cancer","volume":"27","author":"W Chen","year":"2022","journal-title":"Front Biosci (Landmark Ed)"},{"issue":"9","key":"pone.0341154.ref023","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1038\/ng.3375","article-title":"Genomic spectra of biliary tract cancer","volume":"47","author":"H Nakamura","year":"2015","journal-title":"Nat Genet"},{"issue":"4","key":"pone.0341154.ref024","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jhep.2019.05.026","article-title":"Reduction of immunosuppressive tumor microenvironment in cholangiocarcinoma by ex vivo targeting immune checkpoint molecules","volume":"71","author":"G Zhou","year":"2019","journal-title":"J Hepatol"},{"issue":"10391","key":"pone.0341154.ref025","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"RK Kelley","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"pone.0341154.ref026","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"D Husereau","year":"2022","journal-title":"Value Health"},{"issue":"5","key":"pone.0341154.ref027","article-title":"Nivolumab vs pembrolizumab for treatment of US patients with platinum-refractory recurrent or metastatic head and neck squamous cell carcinoma: a network meta-analysis and cost-effectiveness analysis","volume":"4","author":"R Pei","year":"2021","journal-title":"JAMA Netw Open"},{"key":"pone.0341154.ref028","unstructured":"Network NCC. NCCN clinical practice guidelines in oncology: biliary tract cancers, version 2; 2024 [cited 2024 Feb 24]. Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/btc.pdf"},{"issue":"4","key":"pone.0341154.ref029","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1177\/0272989X16670617","article-title":"Estimation of survival probabilities for use in cost-effectiveness analyses: a comparison of a multi-state modeling survival analysis approach with partitioned survival and markov decision-analytic modeling","volume":"37","author":"C Williams","year":"2017","journal-title":"Med Decis Making"},{"issue":"8","key":"pone.0341154.ref030","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40273-013-0064-3","article-title":"Overview of parametric survival analysis for health-economic applications","volume":"31","author":"KJ Ishak","year":"2013","journal-title":"Pharmacoeconomics"},{"key":"pone.0341154.ref031","volume-title":"Chinese guidelines for pharmacoeconomics evaluation 2020","author":"L Gulen","year":"2020"},{"issue":"22","key":"pone.0341154.ref032","doi-asserted-by":"crossref","first-page":"3995","DOI":"10.1002\/cncr.34457","article-title":"Atezolizumab plus bevacizumab versus nivolumab as first-line treatment for advanced or unresectable hepatocellular carcinoma: a cost-effectiveness analysis","volume":"128","author":"Y Li","year":"2022","journal-title":"Cancer"},{"key":"pone.0341154.ref033","doi-asserted-by":"crossref","first-page":"1054405","DOI":"10.3389\/fpubh.2023.1054405","article-title":"Sugemalimab plus chemotherapy vs. chemotherapy for metastatic non-small-cell lung cancer: a cost-effectiveness analysis","volume":"11","author":"X Liang","year":"2023","journal-title":"Front Public Health"},{"issue":"9","key":"pone.0341154.ref034","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness--the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"PJ Neumann","year":"2014","journal-title":"N Engl J Med"},{"key":"pone.0341154.ref035","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"P Guyot","year":"2012","journal-title":"BMC Med Res Methodol"},{"issue":"7","key":"pone.0341154.ref036","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1177\/0272989X19873661","article-title":"Generalized linear models for flexible parametric modeling of the hazard function","volume":"39","author":"B Kearns","year":"2019","journal-title":"Med Decis Making"},{"key":"pone.0341154.ref037","unstructured":"Excellence NIfHaC. NICE DSU technical support document 21. Flexible methods for survival analysis; 2024 [cited 2024 Feb 25]. Available from: http:\/\/www.nicedsu.org.uk"},{"key":"pone.0341154.ref038","doi-asserted-by":"crossref","first-page":"790373","DOI":"10.3389\/fonc.2021.790373","article-title":"Cost-effectiveness analysis of camrelizumab vs. placebo added to chemotherapy as first-line therapy for advanced or metastatic esophageal squamous cell carcinoma in China","volume":"11","author":"Q Zhang","year":"2021","journal-title":"Front Oncol"},{"issue":"3","key":"pone.0341154.ref039","article-title":"Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting","volume":"7","author":"B Wu","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"pone.0341154.ref040","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12962-023-00429-9","article-title":"Cost-effectiveness analysis of adding durvalumab to chemotherapy as first-line treatment for advanced biliary tract cancer based on the TOPAZ-1 trial","volume":"21","author":"Q Zhao","year":"2023","journal-title":"Cost Eff Resour Alloc"},{"issue":"12","key":"pone.0341154.ref041","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1002\/cac2.12110","article-title":"Atezolizumab plus bevacizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma: a cost-effectiveness analysis","volume":"40","author":"Y Hou","year":"2020","journal-title":"Cancer Commun (Lond)"},{"key":"pone.0341154.ref042","doi-asserted-by":"crossref","first-page":"953671","DOI":"10.3389\/fonc.2022.953671","article-title":"Cost-effectiveness analysis of sintilimab vs. placebo in combination with chemotherapy as first-line therapy for local advanced or metastatic oesophageal squamous cell carcinoma","volume":"12","author":"T Shao","year":"2022","journal-title":"Front Oncol"},{"key":"pone.0341154.ref043","unstructured":"Centers for Medicare & Medicaid Services. ASP drug pricing files; 2024 [cited 2024 Apr 22]. Available from: https:\/\/www.cms.gov\/medicare\/medicare-part-b-drug-average-sales-price\/2023-asp-drug-pricing-files"},{"issue":"1","key":"pone.0341154.ref044","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/cam4.1896","article-title":"Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare","volume":"8","author":"DF Sheehan","year":"2019","journal-title":"Cancer Med"},{"issue":"5","key":"pone.0341154.ref045","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1464-410X.2010.09957.x","article-title":"Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma","volume":"108","author":"A Benedict","year":"2011","journal-title":"BJU Int"},{"issue":"1","key":"pone.0341154.ref046","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1186\/s40425-018-0440-9","article-title":"Cost-effectiveness of nivolumab plus ipilimumab as first-line therapy in advanced renal-cell carcinoma","volume":"6","author":"B Wu","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"4","key":"pone.0341154.ref047","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.eururo.2017.07.041","article-title":"Cost effectiveness of nivolumab in advanced renal cell carcinoma","volume":"73","author":"M Sarfaty","year":"2018","journal-title":"Eur Urol"},{"issue":"7","key":"pone.0341154.ref048","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1080\/03007995.2019.1571297","article-title":"Cost-effectiveness of pembrolizumab in combination with chemotherapy versus chemotherapy and pembrolizumab monotherapy in the first-line treatment of squamous non-small-cell lung cancer in the US","volume":"35","author":"RP Insinga","year":"2019","journal-title":"Curr Med Res Opin"},{"key":"pone.0341154.ref049","doi-asserted-by":"crossref","first-page":"878054","DOI":"10.3389\/fonc.2022.878054","article-title":"Pembrolizumab vs cemiplimab for the treatment of advanced non-small cell lung cancer with PD-L1 expression levels of at least 50%: a network meta-analysis and cost-effectiveness analysis","volume":"12","author":"Y Li","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"pone.0341154.ref050","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jval.2020.09.014","article-title":"Assessing the value of cemiplimab for adults with advanced cutaneous squamous cell carcinoma: a cost-effectiveness analysis","volume":"24","author":"G Konidaris","year":"2021","journal-title":"Value Health"},{"issue":"4","key":"pone.0341154.ref051","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0196007","article-title":"Assessment of costs associated with adverse events in patients with cancer","volume":"13","author":"W Wong","year":"2018","journal-title":"PLoS One"},{"issue":"6","key":"pone.0341154.ref052","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00044011-200727060-00002","article-title":"Economic burden of haematological adverse effects in cancer patients: a systematic review","volume":"27","author":"SY Liou","year":"2007","journal-title":"Clin Drug Investig"},{"key":"pone.0341154.ref053","doi-asserted-by":"crossref","first-page":"1046424","DOI":"10.3389\/fpubh.2023.1046424","article-title":"Cost-effectiveness analysis of durvalumab plus chemotherapy as first-line treatment for biliary tract cancer","volume":"11","author":"Z-M Ye","year":"2023","journal-title":"Front Public Health"},{"issue":"5","key":"pone.0341154.ref054","doi-asserted-by":"crossref","DOI":"10.1111\/ajco.12477","article-title":"Health state utilities in non-small cell lung cancer: an international study","volume":"13","author":"B Nafees","year":"2017","journal-title":"Asia Pac J Clin Oncol"},{"issue":"91","key":"pone.0341154.ref055","doi-asserted-by":"crossref","DOI":"10.3310\/hta19910","article-title":"Fluorouracil plasma monitoring: systematic review and economic evaluation of the My5-FU assay for guiding dose adjustment in patients receiving fluorouracil chemotherapy by continuous infusion","volume":"19","author":"K Freeman","year":"2015","journal-title":"Health Technol Assess"},{"issue":"2","key":"pone.0341154.ref056","article-title":"Cost-effectiveness of atezolizumab plus bevacizumab vs sorafenib as first-line treatment of unresectable hepatocellular carcinoma","volume":"4","author":"D Su","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"1","key":"pone.0341154.ref057","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1586\/14737167.1.1.37","article-title":"Incremental cost-effectiveness ratio and incremental net-health benefit: two sides of the same coin","volume":"1","author":"BA Craig","year":"2001","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"pone.0341154.ref058","doi-asserted-by":"crossref","DOI":"10.1177\/0272989X98018002S09","article-title":"Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis","volume":"18","author":"AA Stinnett","year":"1998","journal-title":"Med Decis Making"},{"issue":"4","key":"pone.0341154.ref059","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s12029-016-9885-6","article-title":"A cost-effectiveness analysis of gemcitabine plus cisplatin versus gemcitabine alone for treatment of advanced biliary tract cancer in Japan","volume":"48","author":"I Tsukiyama","year":"2017","journal-title":"J Gastrointest Cancer"},{"issue":"12","key":"pone.0341154.ref060","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/j.jval.2020.08.2094","article-title":"Partitioned survival and state transition models for healthcare decision making in oncology: where are we now?","volume":"23","author":"BS Woods","year":"2020","journal-title":"Value Health"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341154","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:29:16Z","timestamp":1769106556000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0341154"}},"subtitle":[],"editor":[{"given":"Jincheng","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,1,22]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1,22]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0341154","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,22]]}}}